Corvus Pharmaceuticals (CRVS) Profit After Tax Growth (5y) (2020 - 2026)

Corvus Pharmaceuticals (CRVS) Profit After Tax Growth (5y) (2020 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 Corvus Pharmaceuticals 1.17 Bn 934.14 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2026 -3.75%
Sep 30, 2025 -0.73%
Jun 30, 2025 5.50%
Mar 31, 2025 26.01%
Sep 30, 2024 -29.19%
Jun 30, 2024 19.96%
Mar 31, 2024 13.31%
Dec 31, 2023 11.38%
Sep 30, 2023 10.59%
Jun 30, 2023 10.98%
Mar 31, 2023 11.25%
Dec 31, 2022 10.75%
Sep 30, 2022 -3.12%
Jun 30, 2022 11.01%
Mar 31, 2022 12.35%
Dec 31, 2021 0.96%
Sep 30, 2021 -0.74%
Jun 30, 2021 -6.33%
Mar 31, 2021 -12.78%
Dec 31, 2020 45.53%